Juno Therapeutics, Inc. (NASDAQ:JUNO) EVP Robert Azelby sold 1,816 shares of the firm’s stock in a transaction on Monday, December 18th. The stock was sold at an average price of $44.96, for a total transaction of $81,647.36. Following the completion of the sale, the executive vice president now owns 70,832 shares in the company, valued at approximately $3,184,606.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Robert Azelby also recently made the following trade(s):
- On Thursday, November 2nd, Robert Azelby sold 6,666 shares of Juno Therapeutics stock. The stock was sold at an average price of $54.95, for a total value of $366,296.70.
Shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) traded up $0.96 during mid-day trading on Wednesday, reaching $44.71. The company had a trading volume of 2,698,487 shares, compared to its average volume of 2,110,777. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.77 and a quick ratio of 4.77. Juno Therapeutics, Inc. has a 1 year low of $17.52 and a 1 year high of $63.45.
A number of hedge funds have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company grew its position in shares of Juno Therapeutics by 7.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 228 shares during the period. Pacad Investment Ltd. acquired a new position in shares of Juno Therapeutics during the 2nd quarter worth about $105,000. Advisor Group Inc. lifted its holdings in shares of Juno Therapeutics by 141.1% during the 3rd quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 1,439 shares in the last quarter. QS Investors LLC bought a new position in shares of Juno Therapeutics during the 2nd quarter valued at about $135,000. Finally, Bronfman E.L. Rothschild L.P. lifted its holdings in shares of Juno Therapeutics by 27,376.9% during the 3rd quarter. Bronfman E.L. Rothschild L.P. now owns 3,572 shares of the biopharmaceutical company’s stock valued at $160,000 after purchasing an additional 3,559 shares in the last quarter. Hedge funds and other institutional investors own 69.94% of the company’s stock.
Several research analysts recently commented on the company. Cowen reaffirmed a “buy” rating on shares of Juno Therapeutics in a research report on Friday, November 3rd. Raymond James Financial raised their target price on Juno Therapeutics from $45.00 to $61.00 and gave the stock an “outperform” rating in a research report on Friday, November 3rd. Zacks Investment Research cut Juno Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. Wells Fargo & Company cut Juno Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, December 12th. Finally, Citigroup reaffirmed a “buy” rating and issued a $59.00 target price on shares of Juno Therapeutics in a research report on Tuesday, October 31st. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $45.48.
ILLEGAL ACTIVITY NOTICE: This report was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://sportsperspectives.com/2017/12/20/juno-therapeutics-inc-juno-evp-robert-azelby-sells-1816-shares.html.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.